INTRODUCTION {#s1}
============

Cancer is the second most frequently leading cause that caused over 8.8 million deaths worldwide in 2015 \[[@R1]\], and the World Health Organization predicts 14.1 million people are expected to develop cancer annually \[[@R2]\]. Cancer represents a heavy social health problem and economic burden, and costs on patients. The etiology of cancer involves both genetic and environmental factors. Multiple lines of evidence have demonstrated that benzodiazepine drug use is the risk factors for cancer regardless of laboratory studies or animal studies \[[@R3], [@R4]\].

Benzodiazepines are the derivatives of 1, 4-benzodiazepines, including diazepam, flurazepam, chlorazepam, oxazepam and triazolam. The main function of benzodiazepine is inducing feelings of calm, drowsiness and sleep, and have been widely used in clinical, mainly to treat anxiety and insomnia. Benzodiazepines has been one of the most commonly used drugs in the general population for nearly 50 years, with the use of older people worldwide ranging from 10 to 42 percent. In the United States, about 6 to 10 percent of adults use benzodiazepines in 2010, while in Europe, some regions have found a higher proportion \[[@R5], [@R6]\]. Therefore, it is important to evaluate the benzodiazepines drugs safety.

Previous studies have examined the correlation between benzodiazepines drug use and cancer risk \[[@R7]--[@R28]\]. However, the result remains controversial. Additionally, no study to quantitative assessed benzodiazepines drug use in relation to cancer risk. Thus, we performed this dose-response meta-analysis to clarify and quantitative assessed the correlation between benzodiazepines drug use and cancer risk.

RESULTS {#s2}
=======

Literature search results {#s2_1}
-------------------------

Figure [1](#F1){ref-type="fig"} shows literature research and selection. A total of 2304 studies from PubMed, 2638 studies from Embase and 2516 studies from Web of Science. After exclusion of duplicates and studies that did not fulfill the inclusion criteria, 22 studies were chosen, and the data were extracted. These studies were published update to July 2017.

![Flow diagram of the study selection process](oncotarget-08-102381-g001){#F1}

Study characteristics {#s2_2}
---------------------

The characteristics of the included studies of benzodiazepines drug use and cancer risk are shown in the Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Results in different subgroups were treated as two separate reports. Finally, twenty-seven independent reports from twenty two studies investigated the association between benzodiazepines drug use and cancer risk. Among the selected reports, twenty-two are from Caucasia and five from Asia. A total of 2482625 participants with 312203 incident cases from seven countries were included in this meta-analysis.

###### Characteristics of participants in included studies of benzodiazepine using in relation to risk of cancer

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)              Study design         Country                           Sex of population   Age at baseline (years)   No of participants   Endpoints (cases)                           Quality score
  -------------------------- -------------------- --------------------------------- ------------------- ------------------------- -------------------- ------------------------------------------- ---------------
  Coogan et al. (2000)       Case-control         United States                     Mix                 \< 69                     3740                 Ovarian cancer (748)                        6

  Dublin et al. (2002)       Case-control         United States                     Mix                 35--79                    1104                 Ovarian cancer (314)                        7

  Fortuny et al. (2007)      Case-control         United States                     Mix                 66.8                      4110                 Esophageal adenocarcinoma (163)\            8
                                                                                                                                                       Gastric cardia adenocarcinoma (176)\        
                                                                                                                                                       Esophageal squamous cell carcinoma (114)\   
                                                                                                                                                       Gastric non-cardia adenocarcinoma (320)     

  Friedman et al. (1998)     Case-control         United States                     Mix                 30--79                    4403                 Colon cancer (1960)                         7

  Halapy et al. (2006)       Case-control         Canada                            Female              25--74                    6195                 Breast cancer (3133)                        7

  Hardell et al. (1996)      Case-control         Sweden                            Mix                 NA                        987                  Colon cancer (329)                          5

  Harlow et al. (1995)       Case-control         United States                     Mix                 18--80                    904                  Ovarian cancer (450)                        7

  Harnod et al. (2014)       Prospective cohort   China                             Mix                 ≥ 20                      62050                Brain cancer (274)                          7

  Jaussent et al. (2013)     Prospective cohort   France                            Mix                 65--95                    6696                 All cancers (1454)                          8

  Kao et al. (2012)          Prospective cohort   China                             Mix                 47.9                      119239               All cancers (3520)                          6

  Kaufman et al. (1982)      Case-control         Canada,United States and Israel   Female              \< 70                     1964                 Breast cancer (1236)                        6

  Kleinerman et al. (1984)   Case-control         United States                     Female              ≥ 35                      2221                 Breast cancer (1075)                        7

  Kaufman et al. (1990)      Case-control         United States Canada              Female              18--69                    5009                 Breast cancer (3078)                        7

  Rosenberg et al (1995)     Case-control         United States                     Mix                 18--69                    6077                 All cancers (3820)                          7

  Westerdahl et al. (1996)   Case-control         Sweden                            Mix                 15--75                    1040                 Malignant melanoma (400)                    7

  Lagergren et al. (2000)    Case-control         Sweden                            Mix                 \< 80                     1009                 Esophageal cancer (189)                     7

  Pogoda et al. (2005)       Case-control         United States                     Mix                 25--75                    824                  Acute myeloid leukemia (412)                7

  Lagergren et al. (2006)    Case-control         United States                     Female              21--84                    870                  Malignant melanoma (179)                    6

  Kripke et al. (2012)       Prospective cohort   United States                     Female              ≥ 18                      25750                All cancers (2076)                          8

  Pottegardet al. (2012)     Case-control         Denmark                           Mix                 56--74                    1214099              All cancers (149360)                        8

  Iqbal et al. (2015)        Case-control         China                             Mix                 ≥ 20                      255000               All cancers (42500)                         8

  Thygesen et al. (2017)     Case-control         Denmark                           Mix                 18--85                    759334               All cancers (94923)                         7
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Outcomes and covariates of included studies of benzodiazepine using in relation to risk of cancer

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                 Endpoints                                   Data source         Category and relative risk (95% CI)                                                                                                                                                                                   Covariates in fully adjusted model
  ----------------------------- ------------------------------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Coogan et al. (2000)          Ovarian cancer (748)                        Population-based    Duration of regular use 0 using, 1.0 (reference); 0 to 5 years using, 0.9 (0.6, 1.3); more than 5 years using, 1.1 (0.5, 2.3)                                                                                         Adjusted for age, study center, and interview year.

  Dublin et al. (2002)          Ovarian cancer (314)                        Self-administered   Duration of regular use 0 using, 1.0 (reference); 4 months using,0.76 (0.52, 1.10); 6 months using, 0.70 (0.47, 1.0)\                                                                                                 Adjusted for age and reference date.
                                                                                                Number of prescriptions0 prescriptions 1.0 (reference); 1, 0.65 (0.42, 1.0); 2 to 4, 0.91 (0.57, 1.5); \> 5, 0.68 (0.42, 1.1)                                                                                         

  Fortuny et al. (2007)         Esophageal adenocarcinoma (163)\            Population-based    Esophageal adenocarcinoma\                                                                                                                                                                                            Adjusted for age, sex, HMO, years of enrollment in the HMO, race at HFHS, and adjusted for use of drug classes other than the studied one.
                                ,\                                                              Number of prescriptions 0 prescriptions1.0 (reference); \< 1, 1.0 (0.5, 1.7); 1to 5, 0.8 (0.5, 1.5); \> 5, 0.8 (0.4, 1.5)\                                                                                            
                                Gastric cardia adenocarcinoma (176)\                            Gastric cardia adenocarcinoma 0 prescriptions1.0 (reference); \< 1, 0.8 (0.5, 1.3); 1to 5, 0.4 (0.1, 0.9); \> 5, 0.6 (0.3, 1.1)\                                                                                      
                                Esophageal squamous cell carcinoma (114)\                       Esophageal squamous cell carcinoma0 prescriptions 1.0 (reference); \< 1, 0.6 (0.3, 1.2); 1to 5, 0.8 (0.4, 1.9); \> 5, 1.7 (0.9, 3.1)\                                                                                 
                                Gastric non-cardia adenocarcinoma (320)                         Gastric non-cardia adenocarcinoma0 prescriptions 1.0 (reference); \< 1, 0.6 (0.4,0.8); 1to 5, 0.6 (0.4, 1.0); \> 5, 0.5 (0.3, 0.8)                                                                                    

  Friedman et al. (1998)        Colon cancer (1960)                         Population-based    Duration of regular use 0 using, 1.0 (reference); less than 1years using, 0.9 (0.7, 1.3); 1to 5 years using, 1.2 (0.8, 1.8); more than 5 years using, 0.7 (0.3, 1.2)                                                  Age, sex, aspirin and NSAID use,family history of colorectal cancer,body mass index,total calorie, fiber and calcium intake, physical activity, cigarette smoking and alcohol use

  Halapy et al. (2006)          Breast cancer (3133)                        Self-administered   Duration of regular use 0 using, 1.0 (reference);less than 1years using, 0.90 (0.66, 1.22); 1to 6 years using, 1.23 (0.90, 1.69); more than 6 years using, 1.32 (0.95, 1.84)                                          Adjusted for age, family history of breast cancer, and benign breast cysts.

  **Jaussent** et al. (2013)    Colon cancer (329)                          Population-based    Number of prescriptions 0 prescriptions 1.0 (reference); 1, 0.96 (0.74, 1.25); \> 2, 0.93 (0.50, 1.71)                                                                                                                Adjusted for age, study center, and gender; badjusted for all covariates in model 1 plus high level of education, confinement, alcohol intake, smoking status, history of cardio-cerebrovascular disease, respiratory disease, Mini Mental State Examination score, body mass index, hypertension and diabetes mellitus, depressive symptoms, antidepressants use.

  **Kaufman** et al. (1982)     Ovarian cancer (450)                        Self-administered   Duration of regular use 0 using, 1.0 (reference); less than 5 years using, 0.9(0.4, 1.7); more than 5 years using, 1.0 (0.4, 2.6)                                                                                     Age, geographical region, years of education, religion,\
                                                                                                                                                                                                                                                                                                                      parity, age at first pregnancy, menopausal status, age at menopause, history of breast cancer in the mother or sisters, alcohol consumption, number of visits to a doctor in the preceding year, total number of hospital admissions, and year of interview

  Kaufman et al. (1990)         Brain cancer (274)                          Population-based    USDuration of regular use 0 using, 1.0 (reference); less than 5 years using, 1.2 ( 0.7, 2.3); more than 5 years using, 0.7 (0.3, 1.6) Canada\                                                                         Age, Alcohol consumption, medical history,lifetime history of medication use, use of muscle relaxants, tranqulizers, psychiatric drugs, insomnia and pain
                                                                                                Duration of regular use 0 using, 1.0 (reference); less than 5 years using, 0.7 (0.4, 1.3); more than 5 years using, 1.0 (0.5, 2)                                                                                      

  Lagergren et al. (2000)       All cancers (1454)                          Population-based    Duration of regular use 0 using, 1.0 (reference); less than 5 years using, 0.8 (0.6, 3.2); more than 5 years using, 1.5 (0.7, 2.9)                                                                                    Age, sex, body mass index ,tobacco smoking, alcohol use, socioeconomic status (years of formal education), and intake of fruit and vegetables

  **Pottegard** et al. (2012)   All cancers (3520)                          Self-administered   Duration of regular use 0 using, 1.0 (reference); less than 1years using, 1.03 (1.02, 1.05); 1to 3 years using, 1.05 (1.02, 1.08); 3to 7 years using, 1.07 (1.03, 1.12); more than 7 years using, 1.11 (1.01, 1.23)   Age, gender, use of aspirin, non-aspirinNSAIDs, 5-areductase inhibitors, statins, angiotensin-II antagonists, oral contraceptives and hormone supplements, antidepressants, antipsychotics, diagnoses of inflammatory bowel disease, COPD, diabetes, alcohol abuse and Charlson Comorbidity Index score
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Benzodiazepines drug use and overall cancer risk {#s2_3}
------------------------------------------------

Twenty-seven independent reports from twenty two studies investigated the association between between benzodiazepines drug use and cancer risk. Compared with no benzodiazepines drug use, benzodiazepines drug use is significantly associated with a higher risk of cancer risk (RR:1.25; 95% CI, 1.15--1.36; *P* \< 0.001) (Table [3](#T3){ref-type="table"}). Furthermore, benzodiazepines drug use is significantly associated with cancer risk in Caucasia (RR:1.21; 95% CI, 1.05--1.39; *P* \< 0.001) (Table [3](#T3){ref-type="table"}) and Asia (RR:1.36; 95% CI, 1.16--1.59; *P* \< 0.001) (Table [3](#T3){ref-type="table"}). Additionally, benzodiazepines drug use is significantly associated with cancer risk in female (RR:1.14; 95% CI, 1.04--1.24; *P* = 0.004) (Table [3](#T3){ref-type="table"}) but not in male (RR:1.12; 95% CI, 0.96--1.30; *P* = 0.154) (Table [3](#T3){ref-type="table"}). That may be because there isn\'t enough data in male.

###### Stratified analyses of relative risk of cancer

                                      No of reports   Relative risk (95% CI)   P for heterogeneity   I^2^    *P* for test
  ----------------------------------- --------------- ------------------------ --------------------- ------- --------------
  Total                               27              1.25 (1.15--1.36)        0.000                 78.8%   \< 0.001
  Subgroup analyses for cancer                                                                               
  Study location                                                                                             
  Caucasia                            22              1.21 (1.05--1.39)        0.000                 66.3%   0.008
  Asia                                5               1.36 (1.16--1.59)        0.000                 91.0%   \< 0.001
  Gender                                                                                                     
  Female                              10              1.14 (1.04--1.24)        0.015                 56.2%   0.004
  Male                                2               1.12 (0.96--1.30)        0.591                 0.0%    0.154
  Study design                                                                                               
  Case--control                       21              1.15 (1.05--1.26)        0.000                 61.5%   0.002
  Cohort                              6               1.43 (1.12--1.83)        0.000                 92.0%   \< 0.001
  Study quality                                                                                              
  Score ≥ 7                           20              1.27 (1.13--1.42)        0.000                 84.0%   \< 0.001
  Score \< 7                          7               1.20 (1.12--1.29)        0.484                 0.0%    \< 0.001
  No of participants                                                                                         
  ≥ 10 000                            7               1.43 (1.12--1.83)        0.000                 92.0%   \< 0.001
  \< 10 000                           20              1.15 (1.05--1.26)        0.000                 61.5%   0.002
  No of cases                                                                                                
  ≥ 1000                              13              1.26 (1.16--1.37)        0.000                 79.5%   \< 0.001
  \< 1000                             14              1.22 (1.13--1.31)        0.000                 62.9%   \< 0.001
  Types of benzodiazepine                                                                                    
  Long-acting (Diazepam)              8               1.08 (0.94--1.24)        0.075                 50.1%   0.306
  Intermediate-acting                 6               1.21 (1.16--1.23)        0.000                 75.3%   \< 0.001
  Short-acting                        3               1.16 (1.07--1.26)        0.671                 0.0%    \< 0.001
  Duration of benzodiazepine use                                                                             
  0 years                             8               1                                                      
  \< 5 years                          8               1.09 (1.05--1.14)        0.000                 64.6%   \< 0.001
  ≥ 5 years                           8               1.20 (1.16--1.23)        0.000                 72.8%   \< 0.001
  Cumulative yearly dose                                                                                     
  Lower                               3               1                                                      
  Moderate                            3               1.59 (1.26--2.00)        0.000                 62.8%   \< 0.001
  Highest                             3               2.93 (2.45--3.52)        0.000                 96.6%   \< 0.001
  Number of prescriptions                                                                                    
  Lower                               6               1                                                      
  Highest                             6               1.12 (1.03--1.22)        0.069                 51.2%   \< 0.001
  Time since first use                                                                                       
  0 years                             5               1                                                      
  \< 10 years                         5               1.14 (1.05--1.24)        0.753                 0.0%    \< 0.001
  ≥ 10 years                          5               1.23 (1.13--1.33)        0.175                 36.9%   \< 0.001
  Time since last benzodiazpine use                                                                          
  0 years                             2               1                                                      
  \< 1 years                          2               0.97 (0.79--1.20)        0.381                 0.0%    0.781
  ≥ 1 years                           2               1.16 (0.87--1.56)        0.889                 0.0%    0.322

Benzodiazepine drug use and the risk of cancer by type of cancer {#s2_4}
----------------------------------------------------------------

Eleven independent reports from seven studies investigated the association between benzodiazepines drug use and breast cancer. Compared with no benzodiazepines drug use, benzodiazepines drug use is significantly associated with a higher risk of breast cancer (RR:1.15; 95% CI, 1.05--1.26; *P* \< 0.001) (Table [4](#T4){ref-type="table"}). Furthermore, benzodiazepines drug use is significantly associated with breast cancer risk in Caucasia (RR:1.17; 95% CI, 1.08--1.26; *P* \< 0.001) (Table [4](#T4){ref-type="table"}) and Asia (RR:1.09; 95% CI, 1.03--1.16; *P* \< 0.001) (Table [4](#T4){ref-type="table"}). Eight independent reports from six studies investigated the association between benzodiazepines drug use and ovarian cancer risk. Compared with no benzodiazepines drug use, benzodiazepines drug use is significantly associated with a higher risk of ovarian cancer (RR:1.17; 95% CI, 1.09--1.25; *P* \< 0.001) (Table [4](#T4){ref-type="table"}). Furthermore, benzodiazepines drug use is significantly associated with ovarian cancer risk in Caucasia (RR:1.22; 95% CI, 1.15--1.30; *P* \< 0.001) (Table [4](#T4){ref-type="table"}) and Asia (RR:1.11; 95% CI, 1.05--1.17; *P* \< 0.001) (Table [4](#T4){ref-type="table"}). Additionally, Compared with no benzodiazepines drug use, benzodiazepines drug use is significantly associated with a higher risk of colon cancer (RR:1.07; 95% CI, 1.02--1.13; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), renal cancer (RR:1.31; 95% CI, 1.15--1.49; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), malignant melanoma (RR:1.10; 95% CI, 1.03--1.17; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), brain cancer (RR:2.06; 95% CI, 1.76--2.43; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), esophagus cancer (RR:1.55; 95% CI, 1.30--1.85; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), prostate cancer (RR:1.26; 95% CI, 1.16--1.37; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), liver cancer (RR:1.22; 95% CI, 1.13--1.31; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), stomach cancer (RR:1.17; 95% CI, 1.03--1.32; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), pancreatic cancer (RR:1.39; 95% CI, 1.17--1.64; *P* \< 0.001) (Table [4](#T4){ref-type="table"}), lung cancer (RR:1.20; 95% CI, 1.12--1.28; *P* \< 0.001) (Table [4](#T4){ref-type="table"}).

###### Stratified analyses of relative risk of different cancer

                                         No of reports   Relative risk (95% CI)   P for heterogeneity   I^2^    *P* for test
  -------------------------------------- --------------- ------------------------ --------------------- ------- --------------
  Breast cancer                          11              1.15 (1.05--1.25)        0.345                 17.3%   \< 0.001
  Subgroup analyses for Breast cancer                                                                           
  Study location                                                                                                
  Caucasia                               7               1.17 (1.08--1.26)        0.258                 25.6%   \< 0.001
  Asia                                   4               1.09 (1.03--1.16)        0.631                 0.0%    \< 0.001
  Study design                                                                                                  
  Case--control                          8               1.05 (1.01--1.09)        0.214                 23.6%   \< 0.001
  Cohort                                 3               1.19 (1.12--1.28)        0.447                 0.0%    \< 0.001
  Study quality                                                                                                 
  Score ≥ 7                              7               1.06 (1.02--1.10)        0.215                 24.3%   \< 0.001
  Score \< 7                             4               1.19 (1.11--1.28)        0.474                 0.0%    \< 0.001
  No of participants                                                                                            
  ≥ 10 000                               8               1.05 (1.01--1.09)        0.214                 23.6%   \< 0.001
  \< 10 000                              3               1.19 (1.12--1.28)        0.447                 0.0%    \< 0.001
  No of cases                                                                                                   
  ≥ 1500                                 9               1.07 (1.02--1.12)        0.101                 33.6%   \< 0.001
  \< 1500                                2               1.18 (1.10--1.26)        0.673                 0.0%    \< 0.001
  Ovarian cancer                         8               1.17 (1.09--1.25)        0.000                 74.5%   \< 0.001
  Subgroup analyses for Ovarian cancer                                                                          
  Study location                                                                                                
  Caucasia                               4               1.22 (1.15--1.30)        0.008                 80.2%   \< 0.001
  Asia                                   4               1.11 (1.05--1.17)        0.657                 0.0%    \< 0.001
  Study design                                                                                                  
  Case--control                          5               1.14 (1.02--1.28)        0.000                 84.4%   0.012
  Cohort                                 3               1.19 (1.12--1.28)        0.447                 0.0%    \< 0.001
  Study quality                                                                                                 
  Score ≥ 7                              3               1.19 (1.12--1.28)        0.447                 0.0%    \< 0.001
  Score \< 7                             5               1.14 (1.02--1.28)        0.000                 84.4%   0.012
  No of participants                                                                                            
  ≥ 10 000                               3               1.19 (1.12--1.28)        0.447                 0.0%    \< 0.001
  \< 10 000                              5               1.14 (1.02--1.28)        0.000                 84.4%   0.012
  No of cases                                                                                                   
  ≥ 1500                                 3               1.19 (1.12--1.28)        0.447                 0.0%    \< 0.001
  \< 1500                                5               1.14 (1.02--1.28)        0.000                 84.4%   0.012
  Colon cancer                           4               1.07 (1.02--1.13)        0.361                 10.4%   \< 0.001
  Renal cancer                           4               1.31 (1.15--1.49)        0.198                 25.7%   \< 0.001
  Malignant melanoma                     3               1.10 (1.03--1.17)        0.715                 0.0%    \< 0.001
  Brain cancer                           4               2.06 (1.76--2.43)        0.000                 86.1%   \< 0.001
  Esophagus cancer                       4               1.55 (1.30--1.85)        0.679                 0.0%    \< 0.001
  Prostate cancer                        3               1.26 (1.16--1.37)        0.000                 79.5%   \< 0.001
  Liver cancer                           3               1.22 (1.13--1.31)        0.000                 62.9%   \< 0.001
  Stomach cancer                         2               1.17 (1.03--1.32)        0.174                 45.6%   \< 0.001
  Pancreatic cancer                      2               1.39 (1.17--1.64)        0.813                 0.0%    \< 0.001
  Lung cancer                            3               1.20 (1.12--1.28)        0.000                 89.8%   \< 0.001

Subgroup analyses {#s2_5}
-----------------

Subgroup analysis was performed to check the stability of the primary outcome. Subgroup meta-analyses in study design, study quality, number of participants and number of cases showed consistent findings (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

Dose-response between benzodiazepines drug use and cancer risk {#s2_6}
--------------------------------------------------------------

Using restricted cubic spline function, the test for a nonlinear dose-response relationship was significant (likelihood ratio test, *P* \< 0.001), suggesting curvature in the relationship, increasing per 500 mg/year of benzodiazepine drug use was associated with a 17% increment of cancer risk, the summary relative risk of cancer risk for an per 500 mg/year of benzodiazepine drug use was 1.17 (95% CI: 1.02--1.35, *P* = 0.022) (Figure [2](#F2){ref-type="fig"}). In addition, increasing benzodiazepine drug use (per 3 prescriptions increment) was associated with a 16% increment in cancer risk, the summary relative risk of cancer risk for an per 3 prescriptions of benzodiazepine drug use was 1.16 (95% CI: 1.11--1.22, *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}). Furthermore, increasing per 3 year of duration of benzodiazepine drug use was associated with a 5% increment of cancer risk, the summary relative risk of cancer risk for an per 3 year of duration of benzodiazepine drug use was 1.05 (95% CI: 1.02--1.09, *P* = 0.042) (Figure [2](#F2){ref-type="fig"}). Additionally, increasing per 5 year of time since first benzodiazepine drug use was associated with a 4% increment of cancer risk, the summary relative risk of cancer risk for an per 5 year of time since first benzodiazepine drug use was 1.04 (95% CI: 1.01--1.07, *P* = 0.003) (Figure [2](#F2){ref-type="fig"}).

![Dose-response relationship between benzodiazepine drug use in relation to risk of cancer\
(**A**) Cumulative yearly dose of benzodiazepine drug use. (**B**) Number of prescriptions benzodiazepine drug use. (**C**) Duration of benzodiazepine drug use. (**D**) Time since first benzodiazepine drug use.](oncotarget-08-102381-g002){#F2}

Sensitivity analysis {#s2_7}
--------------------

Sensitivity analysis was conducted to assess the stability of the results. The results show the results were stable in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

Publication bias {#s2_8}
----------------

Each studies in this meta-analysis were performed to evaluate the publication bias by both Begg\'s funnel plot and Egger\'s test. *P* \> 0.05 was considered no publication bias. The results show no obvious evidence of publication bias was found in the associations between benzodiazepine drug use and cancer risk ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

Benzodiazepines are widely used to treat seizures, anxiety, insomnia, and panic disorder. In recent years there has been constant evidence that benzodiazepines are associated with cancer risk *in vitro* laboratory and animal studies. Several animal studies reported that benzodiazepines increase the risk of thyroid cancer \[[@R29]\] or liver cancer \[[@R3]\] through inhibiting apoptosis and stimulating tumor cell proliferation. In the meantime, several observational epidemiological studies reported that there was no link between benzodiazepines drug use and the risk cancer. However, recent cohort studies revealed that the use of benzodiazepines drugs was associated with an increased risk of cancer, and the benzodiazepine users were exposed to the risk of benign brain tumor about three times higher than the non-benzodiazepine users. Collectively, these data suggest that benzodiazepines drug use may play an important role in cancer risk, but presented controversial results. Thus, we performed this meta-analysis, aiming to study the role of benzodiazepines in cancer risk and to explain the possible reasons for controversial results.

In the current meta-analysis was based on 22 case-control or cohort study, with 2482625 participants with 312203 incident cases from seven countries. Thus, this meta analysis provides the most up-to-date epidemiological evidence supporting benzodiazepines drug use is harmful for health. A dose-response analysis revealed that increasing per 500 mg/year of benzodiazepine drug use was associated with a 17% increment of cancer risk. In addition, increasing benzodiazepine drug use (per 3 prescriptions increment) was associated with a 16% increment in cancer risk. Furthermore, increasing per 3 year of duration of benzodiazepine drug use was associated with a 5% increment of cancer risk. Additionally, increasing per 5 year of time since first benzodiazepine drug use was associated with a 4% increment of cancer risk. Subgroup meta-analyses by various factors also showed consistent findings.

Several plausible pathways may reasonable for the relationship between benzodiazepine drug use and cancer risk. The influence of chronic inflammation on cancer development is one possible pathway. Benzodiazepine drug use might increase the levels of inflammation mediators \[[@R30]\], which can increase the risk of cancer by inhibiting apoptosis and stimulating tumor cell proliferation \[[@R31]\]. Simultaneously, the treatment of benzodiazepine drug use before surgery can influence the depolarization of the mitochondrial membrane to inhibit the apoptosis of neutrophil cells, neutrophil apoptosis plays an important role in maintaining the homeostasis of the immune system and prevents damage to the host organs by promoting an immune response \[[@R32]\]. Addition, benzodiazepines are used to enhance the neurotransmitter of γ-aminobutyric acid by interacting with the chlorine ion channel that binds to GABA receptors. Besides as an inhibitory neurotransmitter effect, γ-aminobutyric acid is also thought can regulate cell proliferation and differentiation of brain and peripheral at various stages, and may participate in benign tumor growth in a variety of ways \[[@R33], [@R34]\]. However, the potential mechanisms of benzodiazepines and tumor growth still remain unclear and controversial.

To our knowledge, this is the first study to identify and quantify the potential dose-response association between benzodiazepine drug use and cancer risk in a large cohort of both men and women. Although, we performed this meta-analysis very carefully, however, some limitations must be considered in the current meta-analysis. First, different sex of population should be included in this meta-analysis to explore the impact of different sex of population on benzodiazepine drug use and cancer risk. Second, we only select literature that written by English, which may have resulted in a language or cultural bias, other language should be chosen in the further. Third, in the subgroup analysis in cancer type, there has no insufficient statistical power to check a dose-response in different cancer type, large data in different cancer type is warranted to validate this association.

In conclusion, our findings underscore the notion that benzodiazepine drug use was significantly associated with cancer risk increment. In the future, large-scale and population based association studies must be performed in the future to validate the risk identified in the current meta-analysis.

MATERIALS AND METHODS {#s4}
=====================

This meta-analysis was conducted according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) checklist \[[@R35]\].

Search strategy {#s4_1}
---------------

We included eligible studies to investigate the relationship between benzodiazepines drug use and cancer risk. To develop a flexible, non-linear, r meta-regression model, we required that an eligible study should have categorized into 3 or more levels.

PubMed, EMBASE and Web of Science databases were searched for studies that contained risk estimates for the outcomes of cancer and were published update to July 2017, with keywords including "benzodiazepine" \[MeSH\] OR "diazepam" \[MeSH\] OR "alprazolam" \[MeSH\] OR "clonazepam" \[MeSH\] OR "temazepam" \[MeSH\] OR "oxazepam" \[MeSH\] AND "cancer" \[MeSH\] OR "tumor" \[MeSH\] "carcinoma" \[MeSH\] "neoplasm" \[MeSH\]. We refer to the relevant original essays and commentary articles to determine further relevant research.

Study selection {#s4_2}
---------------

Two independent researchers investigate information the correlation between benzodiazepines drug use and cancer risk: outcome was cancer. Moreover, we precluded non-human studies, reviews, meta-analyses, editorials and published letters. To ensure the correct identification of qualified research, the two researchers read the reports independently.

Data extraction {#s4_3}
---------------

Use standardized data collection tables to extract data. Each eligible article information was extracted by two independent researchers. We extracted the following information: first author; publication year; age; country; sex; cases and participants; the categories of benzodiazepines drug use; the relative risk or odds ratio (OR). We collect the risk estimates with multivariable-adjusted. According to the Newcastle-Ottawa scale, quality assessment was performed for non-randomized studies \[[@R36]\].

Statistical analysis {#s4_4}
--------------------

We pooled relative risk estimates to measure the association between benzodiazepines drug use and cancer; the hazard ratio were considered equivalent to the relative risk \[[@R37]\]. Results in different subgroups of benzodiazepines drug use and cancer risk were treated as two separate reports.

Due to different definitions cut-off points in the included studies for categories, we performed a relative risk estimates by increaseper 500mg/year of benzodiazepine using or per 3 prescriptions increment or per 3 year of duration of benzodiazepine using or per 5 year of time since first benzodiazepine use using the method recommended by Greenland, Longnecker and Orsini and colleagues. In addition, using restricted cubic splines to evaluate the non-linear association between benzodiazepines drug use and cancer risk, with three knots at the 10th, 50th, and 90th percentiles of the distribution. A flexible meta-regression based on restricted cubic spline (RCS) function was used to fit the potential non-linear trend, and generalized least-square method was used to estimate the parameters. This procedure treats benzodiazepines drug use (continuous data) as an independent variable and logRR of diseases as a dependent variable, with both tails of the curve restricted to linear. A *P* value is calculated for linear or non-linear by testing the null hypothesis that the coefficient of the second spline is equal to zero \[[@R38]\].

We use STATA software 12.0 (STATA Corp, College Station, TX, USA) to evaluate the relationships between benzodiazepines drug use and cancer risk. By using Q test and I^2^ statistic to assess heterogeneity among studies. Random-effect model was chosen if *P*~Q~\< 0.10 or I^2^ \> 50%, otherwise, fixed-effect mode was applied. Sensitivity analysis was conducted to assess the stability of the results. Begg\'s and Egger\'s tests were to assess the publication bias of each study. *P* \< 0.05 was considered signifcant for all tests.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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